| 망막F-042 |
| 제 3 형 맥락막 신생혈관 치료에 있어서 라니비주맙과 아플리버셉트의 12 개월 치료 효과 비교 |
| 건양대학교 의과대학 김안과 병원 안과학 교실 명곡연구소 |
| 한재욱,김재휘,김철구, 장용석, 김종우, 이동원, |
|
목적 : To compare the outcome of 12 months’ treatment with ranibizumab with that of aflibercept in patients with type 3 neovascularization.
방법 : This retrospective study included 47 treatment-naïve patients with type 3 neovascularization who were treated using either ranibizumab (n = 27) or aflibercept (n = 20) as monotherapy during a 12-month follow-up period. The patients were initially administered 3 monthly injections followed by re-treatment as needed. The bestcorrected visual acuity (BCVA) at diagnosis and at 12 months and number of injections were compared between the 2 groups.
결과 : In the ranibizumab group, the mean BCVA at diagnosis and at 12 months was 0.63 ± 0.36 (20/85 Snellen equivalents) and 0.56 ± 0.48 (20/72), respectively;the equivalent values were 0.75 ± 0.29 (20/112) and 0.67 ± 0.47 (20/93) in the aflibercept group. The mean number of injections was 4.6 ± 1.1 in the ranibizumab group and 4.3 ± 1.1 in the aflibercept group. There was no difference in BCVA at 12 months (P = 0.824) or in the number of injections administered (P = 0.371) between the two groups.
결론 : Intravitreal ranibizumab and aflibercept showed similar efficacy in treating type 3 neovascularization, with a comparable injection frequency.
|
| |